Divestitures	9 Months Ended
Sep. 30, 2026
Discontinued Operations and Disposal Groups [Abstract]
Divestitures	Divestitures By the end of 2024, the Company had substantially completed the previously announced divestitures of its OTC Business, its women’s healthcare business primarily related to oral and injectable contraceptives, its API business in India, its rights to two women’s healthcare products in certain countries, and commercialization rights in the majority of the Upjohn Distributor Markets. During the nine months ended September 30, 2026, the Company recorded additional pre-tax charges of approximately $13.9 million, and during the three and nine months ended September 30, 2025, the Company recorded pre-tax (gain) charges of approximately $(1.6) million and $79.1 million, respectively, primarily related to the divestitures of the OTC and API businesses. The additional charges were recorded as a component of Other Expense, Net in the condensed consolidated statements of operations, and were primarily due to an increase in estimated transaction related costs, including the assumption of additional contractual obligations, as well as the impact of working capital and other transaction-related adjustments. In conjunction with these transactions, Viatris and the respective buyers entered into various agreements to provide a framework for our relationship with the respective buyers after the closing of the divestitures, including transition services agreements, manufacturing and supply agreements, and distribution agreements, some of which include various on-going financial obligations. The transition services and distribution agreements were substantially concluded as of December 31, 2025. Sale of Tyrvaya® Product Rights On August 3, 2026, the Company entered into a definitive agreement to sell the product rights for Tyrvaya® for upfront cash consideration of $30 million and potential contingent sales milestones of up to $70 million. On October 1, 2026, the Company amended and restated the definitive agreement to retain the rights to commercialize Tyrvaya® in Japan, subject to future sales royalties, and subsequently closed the transaction. During the second quarter of 2026, the Company determined that the intangible asset related to Tyrvaya® should be classified as held for sale. Upon classification as held for sale, the Company recognized a charge of $177.8 million to write down the intangible asset to fair value, less cost to sell. During the third quarter of 2026, the Company adjusted the assets and liabilities held for sale, resulting in a gain of $0.8 million. The amounts are included in SG&A on the condensed consolidated statements of operations. The assets and liabilities reclassified as held for sale are included in Prepaid Expenses and Other Current Assets and Other Current Liabilities, respectively, in the condensed consolidated balance sheet.

By the end of 2024, the Company had substantially completed the previously announced divestitures of its OTC Business, its women’s healthcare business primarily related to oral and injectable contraceptives, its API business in India, its rights to two women’s healthcare products in certain countries, and commercialization rights in the majority of the Upjohn Distributor Markets.

During the nine months ended September 30, 2026, the Company recorded additional pre-tax charges of approximately $13.9 million, and during the three and nine months ended September 30, 2025, the Company recorded pre-tax (gain) charges of approximately $(1.6) million and $79.1 million, respectively, primarily related to the divestitures of the OTC and API businesses. The additional charges were recorded as a component of Other Expense, Net in the condensed consolidated statements of operations, and were primarily due to an increase in estimated transaction related costs, including the assumption of additional contractual obligations, as well as the impact of working capital and other transaction-related adjustments.

In conjunction with these transactions, Viatris and the respective buyers entered into various agreements to provide a framework for our relationship with the respective buyers after the closing of the divestitures, including transition services agreements, manufacturing and supply agreements, and distribution agreements, some of which include various on-going financial obligations. The transition services and distribution agreements were substantially concluded as of December 31, 2025.

On August 3, 2026, the Company entered into a definitive agreement to sell the product rights for Tyrvaya® for upfront cash consideration of $30 million and potential contingent sales milestones of up to $70 million. On October 1, 2026, the Company amended and restated the definitive agreement to retain the rights to commercialize Tyrvaya® in Japan, subject to future sales royalties, and subsequently closed the transaction.

During the second quarter of 2026, the Company determined that the intangible asset related to Tyrvaya® should be classified as held for sale. Upon classification as held for sale, the Company recognized a charge of $177.8 million to write down the intangible asset to fair value, less cost to sell. During the third quarter of 2026, the Company adjusted the assets and liabilities held for sale, resulting in a gain of $0.8 million. The amounts are included in SG&A on the condensed consolidated statements of operations. The assets and liabilities reclassified as held for sale are included in Prepaid Expenses and Other Current Assets and Other Current Liabilities, respectively, in the condensed consolidated balance sheet.